Jupiter Topco LLC bought a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 2,129,780 shares of the company’s stock, valued at approximately $261,039,000. Jupiter Topco LLC owned approximately 3.29% of Protagonist Therapeutics as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also made changes to their positions in the stock. BlackRock Inc. bought a new position in shares of Protagonist Therapeutics in the second quarter worth $1,263,535,000. Johnson & Johnson bought a new stake in Protagonist Therapeutics during the second quarter worth $300,220,852,000. Janus Henderson Group PLC boosted its stake in Protagonist Therapeutics by 140.7% in the fourth quarter. Janus Henderson Group PLC now owns 2,649,981 shares of the company’s stock valued at $231,355,000 after buying an additional 1,549,160 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Protagonist Therapeutics by 66.2% during the 4th quarter. Wellington Management Group LLP now owns 3,171,423 shares of the company’s stock valued at $276,992,000 after purchasing an additional 1,262,977 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Protagonist Therapeutics by 27.2% during the fourth quarter. Vanguard Group Inc. now owns 5,413,690 shares of the company’s stock worth $472,832,000 after buying an additional 1,156,461 shares in the last quarter. 98.63% of the stock is currently owned by institutional investors.
Insider Activity
In other Protagonist Therapeutics news, Director William D. Waddill sold 9,000 shares of Protagonist Therapeutics stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $117.94, for a total value of $1,061,460.00. Following the sale, the director owned 7,825 shares of the company’s stock, valued at approximately $922,880.50. The trade was a 53.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Dinesh V. Ph D. Patel sold 34,239 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $148.52, for a total value of $5,085,176.28. Following the completion of the transaction, the chief executive officer owned 523,478 shares in the company, valued at approximately $77,746,952.56. The trade was a 6.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 127,000 shares of company stock worth $17,818,139. Insiders own 5.19% of the company’s stock.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Analysis on Protagonist Therapeutics
Protagonist Therapeutics Price Performance
PTGX opened at $150.59 on Wednesday. Protagonist Therapeutics, Inc. has a 1 year low of $54.50 and a 1 year high of $160.81. The firm’s fifty day moving average price is $136.34 and its two-hundred day moving average price is $111.31. The company has a market capitalization of $9.74 billion, a price-to-earnings ratio of 146.21 and a beta of 1.78.
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $2.29 EPS for the quarter, topping the consensus estimate of $2.27 by $0.02. The firm had revenue of $213.47 million for the quarter, compared to analysts’ expectations of $212.03 million. Protagonist Therapeutics had a net margin of 29.40% and a return on equity of 12.03%. The business’s quarterly revenue was up 3746.8% on a year-over-year basis. As a group, equities analysts anticipate that Protagonist Therapeutics, Inc. will post 4.22 EPS for the current year.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.
Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.
Featured Stories
- Five stocks we like better than Protagonist Therapeutics
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Want to see what other hedge funds are holding PTGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report).
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
